# A randomised prospective trial of CHOP versus MCOP in elderly patients with intermediate and high grade non-Hodgkins lymphoma

Submission date Recruitment status Prospectively registered 01/07/2001 No longer recruiting [ ] Protocol [ ] Statistical analysis plan Registration date Overall study status 01/07/2001 Completed [X] Results [ ] Individual participant data **Condition category** Last Edited 25/01/2019 Cancer

**Plain English summary of protocol**Not provided at time of registration

# Contact information

#### Type(s)

Scientific

#### Contact name

Dr - -

#### Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

## Additional identifiers

ClinicalTrials.gov (NCT) NCT00002576

Protocol serial number NH3003

# Study information

#### Scientific Title

A randomised prospective trial of CHOP versus MCOP in elderly patients with intermediate and high grade non-Hodgkins lymphoma

#### **Study objectives**

Not provided at time of registration

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's)

#### **Interventions**

- 1. CHOP Regimen: Combination chemotherapy, CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone)
- 2. MCOP Regimen: Combination chemotherapy, MCOP (mitozantrone, cyclophosphamide, vincristine, prednisolone)

#### Intervention Type

Drug

#### **Phase**

Not Applicable

#### Drug/device/biological/vaccine name(s)

CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone), MCOP (mitozantrone, cyclophosphamide, vincristine, prednisolone)

#### Primary outcome(s)

Not provided at time of registration

#### Key secondary outcome(s))

Not provided at time of registration

#### Completion date

01/06/2001

# **Eligibility**

#### Key inclusion criteria

- 1. Histologically confirmed intermediate and high grade non-Hodgkin's lymphoma classified as: Diffuse centroblastic; Diffuse immunoblastic; B and T-cell lymphoblastic; Peripheral T-cell of mixed or large cell type; Ki-l
- 2. All stages greater than 1a, non bulky
- 3. Age 65 years and over
- 4. Considered fit enough to receive either regimen
- 5. No previous chemotherapy or radiotherapy 6. No previous malignancy, except non-melanoma skin cancer or adequately treated in-situ cervical carcinoma
- 7. No serious concomitant medical condition that would affect short-term progress
- 8. No severe ischaemic heart disease or cardiomyopathy which could make treatment with adriamycin undesirable

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Senior

#### Sex

Αll

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/01/1996

#### Date of final enrolment

01/06/2001

#### Locations

#### Countries of recruitment

United Kingdom

England

# Study participating centre MRC Clinical Trials Unit

London United Kingdom NW1 2DA

# Sponsor information

#### Organisation

Cancer Research UK (CRUK) (UK)

#### **ROR**

https://ror.org/054225q67

# Funder(s)

#### Funder type

Charity

#### **Funder Name**

Cancer Research UK

#### Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Other non-profit organizations

#### Location

**United Kingdom** 

### **Results and Publications**

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

#### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2003	25/01/2019	Yes	No